Another tumor intrinsic factor driving immune infiltration is tumor mutational load, and this feature has been linked to PD-L1 expression in human tumors [55], immune infiltrates [56, 57], and most importantly clinical response to checkpoint inhibitors [58–60]. The gene discussed is CD274; the disease is neoplasm.